What POP Biotechnologies does

POP Biotechnologies (POP BIO) is a Buffalo, New York-based biotechnology company founded in 2015 that develops nanoparticle-based platform technologies for vaccines, immuno-oncology, and drug delivery. The company's core assets are two patented porphyrin-phospholipid (PoP) liposome technologies. The first, SNAP™ (Spontaneous Nanoliposome Antigen Particleization), uses a protein-tagging approach to embed antigens into liposome nanoparticles, enabling antigen purification in approximately 30 minutes versus several days for conventional methods. The second, Chemophototherapy (CPT), uses PoP liposomes to concentrate chemotherapy drugs within tumors upon exposure to specific laser wavelengths. POP BIO holds an exclusive license from SUNY for the entire SNAP and related patent portfolio, with granted patents spanning the US, EU, China, Japan, India, Canada, and Australia. The company is the US affiliate of Korean vaccine developer EuBiologics and combines its SNAP platform with EuBiologics' proprietary EuIMT immune-enhancing adjuvant.

POP BIO is advancing a pipeline of vaccine candidates targeting H5N1 avian influenza (Phase 1 clinical trial), Severe Fever with Thrombocytopenia Syndrome (SFTS), and RSV and shingles, alongside a mosaic active immunotherapy for Alzheimer's disease. The H5N1 program is funded through CEPI (Coalition for Epidemic Preparedness Innovations) and supports CEPI's 100 Days Mission for pandemic response, while the Alzheimer's program is funded by the NIH. The company operates as a pre-revenue R&D entity with 1-10 employees, generating no commercial sales and funding operations primarily through government and institutional grants.

The business model is grant-funded R&D with no commercial pricing or distribution in place. The company communicates through its company website (pop.bio), press releases distributed via GlobeNewsWire, and partner announcements from CEPI. Future commercialization paths likely involve licensing the SNAP platform to larger pharmaceutical partners, as evidenced by the SNAP patent licensing structure already in place with SUNY. All named end-users for current pipeline programs are public health agencies and clinical trial populations rather than paying commercial customers.

Name

POP Biotechnologies

Legal name

POP Biotechnologies, Inc.

Website

https://popbiotech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

POP Biotechnologies is a Buffalo, NY pre-clinical biotech developing porphyrin-phospholipid (PoP) liposome platform technologies — primarily the SNAP™ nanoparticle vaccine platform and chemophototherapy drug delivery — for infectious disease, oncology, and chronic disease applications. It operates as the US affiliate of Korean vaccine developer EuBiologics and is funded by CEPI and NIH grants.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Platform Technology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)

Keywords

• Nanoparticle vaccine platform
• Porphyrin-phospholipid liposomes
• Chemophototherapy delivery
• Infectious disease vaccines
• Immuno-oncology therapeutics

Headquarters

HQ city

Buffalo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Grant Funding: POP Biotechnologies operates as a pre-revenue research and development company funded primarily through government and institutional grants for vaccine development.

Marketing channels3 records

Core offering

POP Biotechnologies develops proprietary nanoparticle platform technologies—primarily the SNAP (Spontaneous Nanoliposome Antigen Particleization) vaccine platform and Chemophototherapy (CPT)—using patented porphyrin-phospholipid (PoP) liposomes. The company is advancing pipeline candidates including an H5N1 avian influenza vaccine (Phase 1), an Alzheimer's immunotherapy, and an SFTS vaccine, with applications in infectious disease, immuno-oncology, and drug delivery.

Product overview

POP Biotechnologies develops two patented porphyrin-phospholipid (PoP) liposome platform technologies to create nanomedicines. The core SNAP™ (Spontaneous Nanoliposome Antigen Particleization) vaccine platform enables rapid development of highly immunogenic vaccines by embedding antigens into liposome nanoparticles in 30 minutes versus several days. The CPT (Chemophototherapy) platform delivers targeted concentrations of chemotherapy drugs to tumors exposed to laser light. The company is advancing pipeline products including an H5N1 avian influenza vaccine candidate (Phase 1), an Alzheimer's immunotherapy, and an SFTS vaccine, with applications spanning infectious disease, immuno-oncology, and drug delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• SNAP™ Vaccine Platform Spontaneous Nanoliposome Antigen Particleization platform that uses protein-tagging to embed antigens into liposome nanoparticles, enabling approximately 30-minute antigen purification versus several days for conventional methods and producing improved immune response. Licensed for vaccine development across infectious disease, oncology, and chronic diseases.
• Chemophototherapy (CPT) Light-activated drug delivery platform using PoP liposomes to concentrate chemotherapy drugs within tumors exposed to specific laser light, enabling targeted oncology treatment that limits collateral damage to healthy tissues.
• H5N1 Avian Influenza Vaccine Candidate Vaccine candidate targeting H5N1 avian influenza developed using the SNAP nanoparticle platform, advancing into Phase 1 clinical trials in the United States with CEPI funding support.
• Alzheimer's Immunotherapy Mosaic active immunotherapy targeting multiple proteins associated with Alzheimer's disease, leveraging the SNAP platform technology with $2.46M NIH grant support to advance toward human clinical trials.
• SFTS Vaccine Candidate Vaccine candidate targeting Severe Fever with Thrombocytopenia Syndrome (SFTS), being developed on the SNAP nanoparticle platform with initial CEPI funding to support pandemic preparedness.

Quantifiable outcome

• Antigen purification reduced from several days to 30 minutes
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• EuBiologicscoreStrategic or Co-development PartnerEuBiologics is a Korean vaccine developer and parent company of POP Biotechnologies. POP BIO is a U.S. affiliate of EuBiologics, which is leveraging the SNAP platform combined with its proprietary EuIMT immune-enhancing technology for vaccines targeting RSV, shingles, and Alzheimer's disease.
• SUNYcoreOEM/ Whitelabel/ Licensing PartnerPOP Biotechnologies holds an exclusive license from SUNY for the entire SNAP and related patent portfolio, providing the foundational IP for their nanoparticle vaccine platform technology.
• Research Institutes CollaborationsminorStrategic or Co-development PartnerThe NIH-funded Alzheimer's immunotherapy project involves collaborations with research institutes and EuBiologics to develop vaccines for Alzheimer's and other diseases.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• ImmunoVaccine (IMV Inc.): Vaccine platform company developing novel delivery technologies (DepoVax) for infectious disease and immuno-oncology applications. Comparable as a smaller-cap vaccine platform company with a differentiated delivery technology.
• VBI Vaccines: Vaccine platform company developing enveloped virus-like particle (eVLP) and recombinant protein vaccines targeting infectious diseases including RSV and CMV. Comparable as a smaller-cap vaccine platform developer with similar pipeline focus areas.
• CureVac: mRNA-based vaccine platform company developing rapid-response infectious disease vaccines, including CEPI-funded programs. Comparable as a platform technology company pursuing the same 100 Days Mission mandate with smaller scale than Moderna/BioNTech.
• Novavax: Protein subunit nanoparticle vaccine developer (Matrix-M adjuvant platform) targeting infectious disease including influenza and pandemic threats. Most directly comparable to POP BIO's SNAP protein nanoparticle platform with respect to technology class and target indications (H5N1, Disease X).
• Arcturus Therapeutics: Self-amplifying mRNA and lipid nanoparticle delivery platform for vaccines targeting infectious disease including influenza. Comparable as a smaller-cap vaccine platform company pursuing pandemic preparedness applications with proprietary delivery technology.

Broad incumbents

• Translate Bio (acquired by Sanofi): mRNA vaccine and therapeutics platform (now part of Sanofi) with lipid nanoparticle delivery technology. Relevant as a nanoparticle delivery platform peer competing in rapid-response vaccine development.
• Moderna: mRNA-based vaccine and therapeutics platform with deep pandemic preparedness relationships including CEPI funding. Competes with POP BIO for the same rapid-response vaccine mandates and Disease X positioning, but at vastly greater scale.
• BioNTech: Global mRNA vaccine leader (Pfizer partnership) with active pandemic preparedness and infectious disease vaccine programs. Competes for CEPI funding and rapid-response vaccine development mandates that POP BIO also targets.

Others

• EuBiologics: Korean vaccine developer and parent company of POP BIO; partner for SNAP+EuIMT combination programs targeting RSV, shingles and Alzheimer's. Closely tied to POP BIO's pipeline economics and co-development strategy.

Emerging players

• PCI Biotech: Norwegian biotech developing light-triggered drug delivery (photochemical internalization) — directly analogous to POP BIO's CPT/chemophototherapy PoP liposome platform for light-activated targeted drug delivery in oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pop-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about POP Biotechnologies